ET-14 MastHead

Below are releases highlighting the program and research presented at the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics.



Resources

Actelion's Chief Scientific Officer Martine Clozel awarded the Tomoh Masaki award by the 14th International Conferences on Endothelin

Actelion Ltd (SIX: ATLN) today announced that its Chief Scientific Officer and Member of the Actelion Founding team, Martine Clozel, has been awarded the Tomoh Masaki Award by the International Conferences on Endothelin.

IV Administration of Endothelin B Receptor Drug Reduces Memory Loss, Oxidative Stress in Alzheimer’s Disease

Released September 4, 2015 - An estimated 5.3 million people in the U.S. suffer from Alzheimer’s disease (AD). The five current FDA-approved AD medications only help mask the disease symptoms instead of treating the underlying disease. In a new study presented at the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics, researchers used IRL-1620, a chemical that binds to endothelin B receptors, to treat AD in rats.

Vitamin C: The Exercise Replacement?

Released September 4, 2015 - Exercise improves health in overweight and obese adults but can be hard to incorporate into a daily routine. New findings show that taking vitamin C supplements daily instead can have similar cardiovascular benefits as regular exercise in these adults. This study will be presented at 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics in Savannah, Ga.

New Hope for Lou: Unexplored Therapeutic Targets for ALS

Released September 3, 2015 - No cures exist for amyotrophic lateral sclerosis (ALS), and the only approved therapy slows the progression by only a few months. A new study identifies a promising unexplored avenue of treatment for ALS, the endothelin system. This study will be presented at 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics in Savannah, Ga.

International Experts Talk Cancer, Sickle Cell, Diabetic Nephropathy Therapies at Endothelin Meeting in Savannah

Released September 2, 2015 - Endothelin (ET) plays a role in many functions throughout the body, including blood vessel constriction and blood pressure regulation and in a number of disease pathologies. Insights gained through the study of ET have great therapeutic potential for health and disease. As ET experts convene for the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics, the translational aspect of ET research will take center stage during the “Endothelin Therapeutics—Where Are We?” symposium.

One Protein, Many Fascinating Roles

Released September 2, 2015 - Endothelin is a peptide produced by cells in the blood vessels and has powerful vessel-constricting effects. Although mainly associated with its role in blood pressure control and cardiovascular diseases, it continues to appear in other physiological functions and diseases. This symposium, taking place at 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics in Savannah, Ga., will discuss its roles in diabetes, cognitive decline, sickle cell disease and skin pigmentation.

Endothelin-14 Conference to Present Cutting-Edge Therapeutic and Disease Findings

Released August 6, 2015 - APS will host the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics on September 2–5 in Savannah, Ga. The meeting will convene leading global researchers who study endothelin—a type of powerful peptide that constricts blood vessels, raises blood pressure and controls many other cellular functions throughout the body.

From: 
Email:  
To: 
Email:  
Subject: 
Message:

~/Custom.Templates/GrantSec2Columns.aspx